{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:56:06Z","timestamp":1788576966270,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arr.2026.103113","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:32:05Z","timestamp":1775604725000},"page":"103113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates"],"prefix":"10.1016","volume":"118","author":[{"given":"Pradip S.","family":"More","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam W.","family":"Rangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati N.","family":"Lade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha S.","family":"Unidrwade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil S.","family":"Burle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind J.","family":"Umekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radheshyam T.","family":"Lohiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti S.","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10048-025-00821-y","article-title":"Multi-target approach to Alzheimer\u2019s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms","volume":"26","author":"Abbas","year":"2025","journal-title":"Neurogenetics"},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib2","article-title":"APOLLOE4 Phase 3 study of oral ALZ-801\/valiltramiprosate in APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design and baseline characteristics","volume":"10","author":"Abushakra","year":"2024","journal-title":"Alzheimer\u2019S. & Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.arr.2026.103113_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"1","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/bioengineering8020030","article-title":"High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases","volume":"8","author":"Aldewachi","year":"2021","journal-title":"Bioengineering"},{"key":"10.1016\/j.arr.2026.103113_bib5","first-page":"5","article-title":"Use of Caenorhabditis elegans as a model to study Alzheimer\u00e2\u20ac\u2122s disease and other neurodegenerative diseases","author":"Alexander","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.arr.2026.103113_bib6","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.2147\/DDDT.S367229","article-title":"Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: a review of literature","volume":"16","author":"Alhowail","year":"2022","journal-title":"Drug Des. Devel Ther."},{"issue":"12","key":"10.1016\/j.arr.2026.103113_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","article-title":"Drug repositioning and repurposing for Alzheimer disease","volume":"16","author":"Ballard","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.arr.2026.103113_bib8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","article-title":"APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry","volume":"80","author":"Belloy","year":"2023","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib9","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"2016","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.31887\/DCNS.2009.11.2\/hbrodaty","article-title":"Family caregivers of people with dementia","volume":"11","author":"Brodaty","year":"2009","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"41","key":"10.1016\/j.arr.2026.103113_bib11","doi-asserted-by":"crossref","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","article-title":"Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy","volume":"30","author":"Brunden","year":"2010","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer\u2019s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.arr.2026.103113_bib13","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib15","first-page":"17","article-title":"Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs","author":"Carraro","year":"2024","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib16","first-page":"12","article-title":"Alzheimer\u2019s Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits","author":"Chatterjee","year":"2018","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib17","article-title":"Repurposing doxycycline for Alzheimer\u2019s treatment: Challenges from a nano-based drug delivery perspective","volume":"42","author":"Concei\u00e7\u00e3o","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"issue":"11","key":"10.1016\/j.arr.2026.103113_bib18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and Tolerability of the \u03b3-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13024-025-00894-1","article-title":"Effect of antidiabetic drugs in Alzheimer\u00b4s disease: a systematic review of preclinical and clinical studies","volume":"20","author":"Corraliza-Gomez","year":"2025","journal-title":"Mol. Neurodegener."},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nrd3706","article-title":"RXR agonist reverses Alzheimer\u2019s disease","volume":"11","author":"Crunkhorn","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.trci.2018.04.008","article-title":"The price of progress: Funding and financing Alzheimer\u2019s disease drug development","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimer\u2019S. & Dement. Transl. Res. & Clin. Interv."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib22","article-title":"Who funds Alzheimer\u2019s disease drug development","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimer\u2019S. & Dement. Transl. Res. & Clin. Interv."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib23","article-title":"Alzheimer\u2019s disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019S. & Dement. Transl. Res. & Clin. Interv."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100001","article-title":"Key considerations for combination therapy in Alzheimer\u2019s clinical trials: Perspectives from an expert advisory board convened by the Alzheimer\u2019s drug discovery foundation","volume":"12","author":"Cummings","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41467-025-56690-4","article-title":"Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"16","author":"Cummings","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","article-title":"Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government","volume":"21","author":"van der Pol","year":"2023","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"9","key":"10.1016\/j.arr.2026.103113_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11910-018-0863-1","article-title":"Viral Hypothesis and Antiviral Treatment in Alzheimer\u2019s Disease","volume":"18","author":"Devanand","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11033-023-09021-z","article-title":"Oxidative stress in Alzheimer\u2019s disease: current knowledge of signaling pathways and therapeutics","volume":"51","author":"Dhapola","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","article-title":"Heterogeneity in Alzheimer\u2019s Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials","volume":"19","author":"Duara","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.arr.2026.103113_bib31","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jpsychires.2013.02.013","article-title":"Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice","volume":"47","author":"Engel","year":"2013","journal-title":"J. Psychiatr. Res"},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1039\/D4CP03291H","article-title":"Computational insights in repurposing a cardiovascular drug for Alzheimer\u2019s disease: the role of aromatic amino acids in stabilizing the drug through \u03c0\u2013\u03c0 stacking interaction","volume":"27","author":"Esther Rubavathy","year":"2025","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-021-00951-z","article-title":"Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer\u2019s disease","volume":"14","author":"Fang","year":"2022","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1742-2094-9-62","article-title":"Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer\u2019s disease-like amyloid pathology","volume":"9","author":"Ferretti","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/cn5000309","article-title":"Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer\u2019s Disease and Related Neurodegenerative Disorders","volume":"5","author":"Forlenza","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"s1","key":"10.1016\/j.arr.2026.103113_bib37","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3233\/JAD-179921","article-title":"Multifactorial Hypothesis and Multi-Targets for Alzheimer\u2019s Disease","volume":"64","author":"Gong","year":"2018","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.arr.2026.103113_bib38","first-page":"14","article-title":"Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer\u2019s Disease","author":"Gong","year":"2022","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib39","first-page":"14","article-title":"Drug repurposing for Alzheimer\u2019s disease from 2012 to 2022\u2014a 10-year literature review","author":"Grabowska","year":"2023","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 Variants in Alzheimer\u2019s Disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2026.103113_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105558","article-title":"Pursuit of precision medicine: Systems biology approaches in Alzheimer\u2019s disease mouse models","volume":"161","author":"Gurdon","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2026.103113_bib42","first-page":"12","article-title":"Class I HDAC Inhibitor Improves Synaptic Proteins and Repairs Cytoskeleton Through Regulating Synapse-Related Genes In vitro and In vivo","author":"Han","year":"2021","journal-title":"Front Aging Neurosci."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib43","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPAR\u03b3 agonist pioglitazone and ibuprofen reduces glial inflammation and A\u03b21\u201342 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","article-title":"\u03b3-Secretase in Alzheimer\u2019s disease","volume":"54","author":"Hur","year":"2022","journal-title":"Exp. Mol. Med"},{"issue":"5","key":"10.1016\/j.arr.2026.103113_bib46","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer\u2019s Disease: A Population-Based Case\u2013Control Study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"S5","key":"10.1016\/j.arr.2026.103113_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/alz70859_102227","article-title":"Repurposed Drug Prioritisation Pipeline for an Alzheimer\u2019s Disease Multi-arm Platform Trial","volume":"21","author":"Iqbal","year":"2025","journal-title":"Alzheimer\u2019S. & Dement."},{"issue":"14","key":"10.1016\/j.arr.2026.103113_bib48","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.3390\/ijms21144920","article-title":"The Use of Antimicrobial and Antiviral Drugs in Alzheimer\u2019s Disease","volume":"21","author":"Iqbal","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"7784","key":"10.1016\/j.arr.2026.103113_bib49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/proteomes11040034","article-title":"Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers","volume":"11","author":"Ivanisevic","year":"2023","journal-title":"Proteomes"},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer\u2019s disease neuroimaging initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J. Magn. Reson. Imaging"},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer\u2019s disease neuroimaging initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J. Magn. Reson. Imaging"},{"issue":"21","key":"10.1016\/j.arr.2026.103113_bib53","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.3390\/ijms222111520","article-title":"Disentangling Mitochondria in Alzheimer\u2019s Disease","volume":"22","author":"Johri","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10787-024-01608-7","article-title":"Drugs repurposing in the experimental models of Alzheimer\u2019s disease","volume":"33","author":"Joodi","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"28","key":"10.1016\/j.arr.2026.103113_bib55","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2174\/0115680266360664250606110220","article-title":"Histone Deacetylase Inhibition in Alzheimer\u2019s Disease: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives","volume":"25","author":"Joshi","year":"2025","journal-title":"Curr. Top. Med Chem."},{"key":"10.1016\/j.arr.2026.103113_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Inter. Aging"},{"key":"10.1016\/j.arr.2026.103113_bib57","first-page":"17","article-title":"Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer\u2019s disease","author":"Khan","year":"2026","journal-title":"Front Aging Neurosci."},{"issue":"50","key":"10.1016\/j.arr.2026.103113_bib58","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.arr.2026.103113_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib60","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv. Res"},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/fcp.12872","article-title":"Role of angiotensin receptor blockers in the context of Alzheimer\u2019s disease","volume":"37","author":"Kuber","year":"2023","journal-title":"Fundam. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and Molecular Mechanisms of Metformin Action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib63","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/1673-5374.226379","article-title":"Neuroprotective effects of statins against amyloid \u03b2-induced neurotoxicity","volume":"13","author":"Li","year":"2018","journal-title":"Neural Regen. Res"},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib64","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41598-025-85947-7","article-title":"DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer\u2019s disease","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2026.103113_bib65","first-page":"12","article-title":"Deciphering the Roles of Metformin in Alzheimer\u2019s Disease: A Snapshot","author":"Liao","year":"2022","journal-title":"Front Pharm."},{"issue":"8","key":"10.1016\/j.arr.2026.103113_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271348","article-title":"Intracranial approach for sub-second monitoring of neurotransmitters during DBS electrode implantation does not increase infection rate","volume":"17","author":"Liebenow","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.arr.2026.103113_bib67","article-title":"Galantamine for dementia due to Alzheimer\u2019s disease and mild cognitive impairment","volume":"2024","author":"Lim","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.arr.2026.103113_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102021","article-title":"The novel function of bexarotene for neurological diseases","volume":"90","author":"Liu","year":"2023","journal-title":"Ageing Res Rev."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/brainsci15020164","article-title":"Effect of N-Acetyl Cysteine as an Adjuvant Treatment in Alzheimer\u2019s Disease","volume":"15","author":"Lomel\u00ed Mart\u00ednez","year":"2025","journal-title":"Brain Sci."},{"issue":"11","key":"10.1016\/j.arr.2026.103113_bib71","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.15419\/s00m4g68","article-title":"Unravelling Alzheimer\u2019s Disease: Therapeutic Strategies Aimed at neuroinflammation signalling pathway","volume":"12","author":"Long","year":"2025","journal-title":"Biomed. Res. Ther."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/17425255.2025.2503848","article-title":"Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far","volume":"21","author":"Mangoni","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11011-025-01664-0","article-title":"Exploration of Imatinib involved in amyloidogenesis as a common foundation for type-2 diabetes mellitus (T2DM) and Alzheimer\u2019s disease (AD)","volume":"40","author":"Mannan","year":"2025","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib75","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209419","article-title":"Continuous \u03b2-Amyloid CSF\/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity","volume":"103","author":"Mastenbroek","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103113_bib76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib77","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.3390\/cimb46060354","article-title":"Unlocking the Potential: Semaglutide\u2019s Impact on Alzheimer\u2019s and Parkinson\u2019s Disease in Animal Models","volume":"46","author":"Meca","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.arr.2026.103113_bib78","first-page":"14","article-title":"Alzheimer\u2019s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?","author":"Melchiorri","year":"2023","journal-title":"Front Pharm."},{"issue":"12","key":"10.1016\/j.arr.2026.103113_bib79","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0169-409X(02)00162-X","article-title":"Neuroinflammation and anti-inflammatory therapy for Alzheimer\u2019s disease","volume":"54","author":"Moore","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.arr.2026.103113_bib80","doi-asserted-by":"crossref","unstructured":"Mottaqi M., Zhang P., Xie L. Integrating explainable AI with multiomics systems biology and EHR data mining for personalized drug repurposing in Alzheimer\u2019s disease. 2025. doi:\u300810.1101\/2025.03.24.644676\u3009.","DOI":"10.1101\/2025.03.24.644676"},{"issue":"8","key":"10.1016\/j.arr.2026.103113_bib81","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/antiox9080676","article-title":"SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer\u2019s Disease-Like Pathology in OXYS Rats","volume":"9","author":"Muraleva","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.arr.2026.103113_bib82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","article-title":"Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice","volume":"69","author":"Ou","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"8","key":"10.1016\/j.arr.2026.103113_bib83","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","article-title":"Insights into Computational Drug Repurposing for Neurodegenerative Disease","volume":"40","author":"Paranjpe","year":"2019","journal-title":"Trends Pharm. Sci."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib84","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2026.103113_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102698","article-title":"Repurposing drugs: promising therapeutic approach against Alzheimer\u2019s disease","volume":"106","author":"Pattanaik","year":"2025","journal-title":"Ageing Res Rev."},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104052","article-title":"Restoring the epigenome in Alzheimer\u2019s disease: advancing HDAC inhibitors as therapeutic agents","volume":"29","author":"Pereira","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib87","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008732","article-title":"Investigation of antihypertensive class, dementia, and cognitive decline","volume":"94","author":"Peters","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2026.103113_bib89","first-page":"4","article-title":"How drug repurposing can advance drug discovery: challenges and opportunities","author":"Pinzi","year":"2024","journal-title":"Front. Drug Discov."},{"issue":"5","key":"10.1016\/j.arr.2026.103113_bib90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbadis.2011.10.003","article-title":"Elevation of glutathione as a therapeutic strategy in Alzheimer disease","volume":"1822","author":"Pocernich","year":"2012","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib91","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.arr.2026.103113_bib92","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/hmg\/ddx052","article-title":"Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer\u2019s disease","volume":"26","author":"Reddy","year":"2017","journal-title":"Hum. Mol. Genet"},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib93","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3233\/JAD-170988","article-title":"Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer\u2019s Disease","volume":"62","author":"Reddy","year":"2018","journal-title":"J. Alzheimer\u2019S. Dis."},{"issue":"14","key":"10.1016\/j.arr.2026.103113_bib94","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/cells14141064","article-title":"Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress","volume":"14","author":"Reed","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.arr.2026.103113_bib95","doi-asserted-by":"crossref","unstructured":"Regulatory considerations and intellectual property rights of repurposed drugs. In. 2024. p. 357\u201375. doi:\u300810.1016\/bs.pmbts.2024.03.019\u3009.","DOI":"10.1016\/bs.pmbts.2024.03.019"},{"issue":"14","key":"10.1016\/j.arr.2026.103113_bib96","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in Moderate-to-Severe Alzheimer\u2019s Disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00553","article-title":"Utilization of precision medicine digital twins for drug discovery in Alzheimer\u2019s disease","volume":"22","author":"Ren","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2026.103113_bib98","first-page":"15","article-title":"Reassessment of Pioglitazone for Alzheimer\u2019s Disease","author":"Saunders","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib99","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.csbj.2022.03.013","article-title":"Network-based stage-specific drug repurposing for Alzheimer\u2019s disease","volume":"20","author":"Savva","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for <scp>A<\/scp> lzheimer\u2019s disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern Med"},{"key":"10.1016\/j.arr.2026.103113_bib101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.coph.2021.09.002","article-title":"New trends in pharmacological control of neuropsychiatric symptoms of dementia","volume":"61","author":"Scuteri","year":"2021","journal-title":"Curr. Opin. Pharm."},{"issue":"6","key":"10.1016\/j.arr.2026.103113_bib102","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med"},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib103","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019s Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study","volume":"33","author":"del Ser","year":"2012","journal-title":"J. Alzheimer\u2019S. Dis."},{"issue":"7618","key":"10.1016\/j.arr.2026.103113_bib104","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.arr.2026.103113_bib105","first-page":"9","article-title":"Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer\u2019s Disease","author":"Shityakov","year":"2021","journal-title":"Front Chem."},{"key":"10.1016\/j.arr.2026.103113_bib106","first-page":"11","article-title":"Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation","author":"Shukla","year":"2020","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib107","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/JAD-2011-111391","article-title":"Mitochondria-Targeted Antioxidants as Promising Drugs for Treatment of Age-Related Brain Diseases","volume":"28","author":"Skulachev","year":"2012","journal-title":"J. Alzheimer\u2019S. Dis."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib108","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1038\/s41598-023-31281-9","article-title":"Mitochondrion-targeted antioxidant SkQ1 prevents rapid animal death caused by highly diverse shocks","volume":"13","author":"Skulachev","year":"2023","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.arr.2026.103113_bib109","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1089\/ars.2011.3969","article-title":"Mitochondria-Targeted Small Molecule Therapeutics and Probes","volume":"15","author":"Smith","year":"2011","journal-title":"Antioxid. Redox Signal"},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib110","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.neurobiolaging.2008.07.021","article-title":"Co-occurrence of Alzheimer\u2019s disease \u03b2-amyloid and tau pathologies at synapses","volume":"31","author":"Takahashi","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.arr.2026.103113_bib111","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.3390\/jcm13113098","article-title":"Novel Therapeutic Strategies in Alzheimer\u2019s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond","volume":"13","author":"Tondo","year":"2024","journal-title":"J. Clin. Med"},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib112","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tips.2024.05.005","article-title":"Multi-target drugs for Alzheimer\u2019s disease","volume":"45","author":"Turgutalp","year":"2024","journal-title":"Trends Pharm. Sci."},{"issue":"5","key":"10.1016\/j.arr.2026.103113_bib113","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph18050614","article-title":"Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer\u2019s Disease","volume":"18","author":"Urkon","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.arr.2026.103113_bib114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mito.2021.04.005","article-title":"Protective effects of a small molecule inhibitor, DDQ against amyloid beta in Alzheimer\u2019s disease","volume":"59","author":"Vijayan","year":"2021","journal-title":"Mitochondrion"},{"issue":"7","key":"10.1016\/j.arr.2026.103113_bib115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/hmg\/ddab285","article-title":"Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimer\u2019s disease","volume":"31","author":"Vijayan","year":"2022","journal-title":"Hum. Mol. Genet"},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib116","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.arr.2026.103113_bib117","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/ene.12564","article-title":"Site-specific clinical disease onset in multiple sclerosis","volume":"22","author":"Willis","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.arr.2026.103113_bib118","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer\u2019s Disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimer\u2019S. Dis."},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib119","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1756285610370069","article-title":"Antiviral agents in Alzheimer\u2019s disease: hope for the future?","volume":"3","author":"Wozniak","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.arr.2026.103113_bib120","first-page":"10","article-title":"Hybrid neural network approaches to predict drug\u2013target binding affinity for drug repurposing: screening for potential leads for Alzheimer\u2019s disease","author":"Wu","year":"2023","journal-title":"Front Mol. Biosci."},{"issue":"3","key":"10.1016\/j.arr.2026.103113_bib121","doi-asserted-by":"crossref","first-page":"255","DOI":"10.37349\/en.2024.00048","article-title":"Current therapeutics for Alzheimer\u2019s disease and clinical trials","volume":"3","author":"Xiao","year":"2024","journal-title":"Explor. Neurosci."},{"key":"10.1016\/j.arr.2026.103113_bib122","first-page":"12","article-title":"Computational Drug Repurposing for Alzheimer\u2019s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies","author":"Xu","year":"2021","journal-title":"Front Pharm."},{"issue":"5","key":"10.1016\/j.arr.2026.103113_bib123","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/ijms25052945","article-title":"Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases","volume":"25","author":"Yamashita","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-017-0089-1","article-title":"The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer\u2019s disease","volume":"6","author":"Yang","year":"2017","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib125","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1038\/s41467-023-43929-1","article-title":"High-throughput target trial emulation for Alzheimer\u2019s disease drug repurposing with real-world data","volume":"14","author":"Zang","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.arr.2026.103113_bib126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.arr.2026.103113_bib127","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Investig."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726001054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726001054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:20:52Z","timestamp":1778822452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163726001054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":127,"alternative-id":["S1568163726001054"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2026.103113","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2026.103113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103113"}}